Autopsy report · NCT04167618

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

“Business priorities”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 11 months before it started.
• Ran for about 10 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Y-mAbs Therapeutics

Sponsor type

Industry

Conditions

Medulloblastoma, Childhood

Interventions

177Lu-DTPA-omburtamab

Participants

2

Sites

10

Countries

Denmark, Netherlands, Spain, United Kingdom, United States

Trials that died the same way

• A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures
  “Change in business priorities.” (81% match in meaning)
• MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction
  “Change in business priority” (74% match in meaning)
• Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
  “Change in company priorities” (71% match in meaning)
• Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate
  “Business considerations” (68% match in meaning)
• Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
  “Business Decision” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.